Status:
COMPLETED
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
Lead Sponsor:
GlaxoSmithKline
Conditions:
Arthritis, Rheumatoid
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study is being conducted to find out if an investigational drug called GW406381 can help people with rheumatoid arthritis.
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Rheumatoid arthritis (RA) for at least 12 months.
- Required a non-steroidal anti-inflammatory drug (NSAID) or COX-2 inhibitor for RA for at least 5 out of 7 days of each week for the 4 weeks prior to screening.
- Exclusion criteria:
- Any history of cardiovascular disease (e.g., heart attack, stroke, congestive heart failure, uncontrolled high blood pressure), documented peripheral arterial insufficiency and symptomatic, clinically significant claudication, or who have a history of peripheral arterial embolism.
- Have an active stomach ulcer or history of any stomach tear or bleeding.
Exclusion
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2006
Estimated Enrollment :
2208 Patients enrolled
Trial Details
Trial ID
NCT00113308
Start Date
June 1 2005
End Date
September 1 2006
Last Update
March 14 2017
Active Locations (341)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Anniston, Alabama, United States, 36207
2
GSK Investigational Site
Birmingham, Alabama, United States, 35205
3
GSK Investigational Site
Birmingham, Alabama, United States, 35215
4
GSK Investigational Site
Huntsville, Alabama, United States, 35801